A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
Administered By
Awarded By
Contributors
- Beerman, Rebecca Project Manager
- Montefiori, David Charles Principal Investigator
- Sarzotti-Kelsoe, Marcella Director
- Shen, Xiaoying Co Investigator
Start/End
- June 9, 2021 - June 9, 2023